| 臺大學術典藏 |
2020-10-14T07:24:37Z |
Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
|
Wong J.-M.; SHU-CHEN WEI; Wang H.-Y.; Yen H.-H.; Hsu W.-H.; Lin H.-H.; Lin J.-K.; Chuang C.-H.; Huang T.-Y.; Chou J.-W.; Lin W.-C. |
| 臺大學術典藏 |
2020-09-23T06:22:46Z |
Differentiating solitary pulmonary metastases in patients with extrapulmonary neoplasmas using FDG-PET
|
Hsu W.-H.;Hsu N.-Y.;Shen Y.-Y.;Ruoh-Fang Yen;Kao C.-H.; Hsu W.-H.; Hsu N.-Y.; Shen Y.-Y.; RUOH-FANG YEN; Kao C.-H. |
| 臺大學術典藏 |
2020-08-14T03:15:32Z |
Management of Crohn's disease in Taiwan: Consensus guideline of the Taiwan society of inflammatory bowel disease
|
Lin J.-K.; Lin W.-C.; Ni Y.-H.; Shieh M.-J.; I-LUN SHIH; Shun C.-T.; Tsang Y.-M.; Wang C.-Y.; Wang H.-Y.; Weng M.-T.; Wu D.-C.; Wu W.-C.; Yen H.-H.; Wong J.-M.; Lin C.-C.; Huang T.-Y.; Hsu T.-C.; Hsu W.-H.; Chuang C.-H.; Chou Y.-H.; Chou J.-W.; Chen J.-S.; Chao T.-H.; Chang T.-A.; Wei S.-C.; Wei S.-C.;Chang T.-A.;Chao T.-H.;Chen J.-S.;Chou J.-W.;Chou Y.-H.;Chuang C.-H.;Hsu W.-H.;Huang T.-Y.;Hsu T.-C.;Lin C.-C.;Lin H.-H.;Lin J.-K.;Lin W.-C.;Ni Y.-H.;Shieh M.-J.;I-Lun Shih;Shun C.-T.;Tsang Y.-M.;Wang C.-Y.;Wang H.-Y.;Weng M.-T.;Wu D.-C.;Wu W.-C.;Yen H.-H.;Wong J.-M.; Lin H.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:46Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; Yu C.-J.; JIN-YUAN SHIH; Lin C.-C.; Chen K.-Y.; Ho C.-C.; Laio W.-Y.; Yang P.-C.; Yang J.C.-H.; Lee J.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:33Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Yang J.C.; Yu C.-J.; JIN-YUAN SHIH; Lin C.-C.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Chen K.-Y.; Liao W.-Y.; Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Jin-Yuan Shih;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:24Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Tsai T.-H.; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yang C.-Y.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Jin-Yuan Shih;Yang J.C.-H.;Yu C.-J.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; JIN-YUAN SHIH; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-13T06:33:24Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yu C.-J.; Yang J.C.-H.; JIN-YUAN SHIH; Lin C.-C.; Lee J.-H.; Hsu W.-H.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu C.-L.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Jin-Yuan Shih;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H. |
| 臺大學術典藏 |
2020-08-12T07:46:56Z |
Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists
|
Chen C.-Y.; On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE); Lai C.-C.; HAO-CHIEN WANG; Chen L.; Yu C.-J.; Yu C.-J.; HAO-CHIEN WANG; Perng D.-W.; Cheng S.-L.; Hsu J.-Y.; Hsu W.-H.; Tsai Y.-H.; Hsiue T.-R.; Lin M.-C.; Lin H.-I.; Wang C.-Y.; Chang Y.-C.; Yang U.-C.; Chen C.-M.; Lin C.-S.; Chen L.; Wei Y.-F.; Chong I.-W.; Wang Y.-H.; Lin Y.S.; Wang C.-Y.; Wang C.-Y.;Lin Y.S.;Wang Y.-H.;Lai C.-C.;Hao-Chien Wang;Chen L.;Yu C.-J.;Yu C.-J.;Hao-Chien Wang;Perng D.-W.;Cheng S.-L.;Hsu J.-Y.;Hsu W.-H.;Tsai Y.-H.;Hsiue T.-R.;Lin M.-C.;Lin H.-I.;Wang C.-Y.;Chang Y.-C.;Yang U.-C.;Chen C.-M.;Lin C.-S.;Chen L.;Wei Y.-F.;Chong I.-W.;Chen C.-Y.;On The Behalf Of Taiwan Clinical Trial Consortium For Respiratory Diseases (Tcore) |
| 臺大學術典藏 |
2020-08-12T06:34:18Z |
Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists
|
Wang C.-Y.; Lin Y.S.; Wang Y.-H.; Lai C.-C.; Wang H.-C.; Chen L.; CHONG-JEN YU; CHONG-JEN YU; Wang H.-C.; Perng D.-W.; Cheng S.-L.; Hsu J.-Y.; Hsu W.-H.; Tsai Y.-H.; Hsiue T.-R.; Lin M.-C.; Lin H.-I.; Wang C.-Y.; Chang Y.-C.; Yang U.-C.; Chen C.-M.; Lin C.-S.; Chen L.; Wei Y.-F.; Chong I.-W.; Chen C.-Y.; On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE); Wang C.-Y.;Lin Y.S.;Wang Y.-H.;Lai C.-C.;Wang H.-C.;Chen L.;Chong-Jen Yu;Chong-Jen Yu;Wang H.-C.;Perng D.-W.;Cheng S.-L.;Hsu J.-Y.;Hsu W.-H.;Tsai Y.-H.;Hsiue T.-R.;Lin M.-C.;Lin H.-I.;Wang C.-Y.;Chang Y.-C.;Yang U.-C.;Chen C.-M.;Lin C.-S.;Chen L.;Wei Y.-F.;Chong I.-W.;Chen C.-Y.;On The Behalf Of Taiwan Clinical Trial Consortium For Respiratory Diseases (Tcore) |
| 臺大學術典藏 |
2020-08-12T06:34:15Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Hsu C.-C.; Wu C.-T.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Yang C.-Y.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020-08-12T02:50:41Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Chao-Chi Ho;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; CHAO-CHI HO; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T02:50:36Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Wu C.-T.; Chang Y.-L.; Yang C.-Y.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y. |
| 臺大學術典藏 |
2020-08-12T02:50:35Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-07T01:43:04Z |
Elderly Adults with Late-Onset Ulcerative Colitis Tend to Have Atypical, Milder Initial Clinical Presentations but Higher Surgical Rates and Mortality: A Taiwan Society of Inflammatory Bowel Disease Study
|
Wong J.-M.; Lin W.-C.; CHIEN-CHIH TUNG; Lin H.-H.; Lin C.-C.; Chang C.-W.; Yen H.-H.; Chuang C.-H.; Hsu W.-H.; Tsai W.-S.; Wang H.-Y.; Lin J.-K.; Wei S.-C. |
| 臺大學術典藏 |
2020-07-21T06:46:29Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Yang J.C.-H.; Lee J.-H.; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Chen K.-Y.; CHAO-CHI HO; Laio W.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-07-21T06:46:21Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin C.-C.; Lee J.-H.; Chang Y.-L.; Su K.-Y.; Hsu W.-H.; Hsu C.-L.; Tsai T.-H.; Chen K.-Y.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; CHAO-CHI HO; Liao W.-Y.; Yu C.-J.; Yang J.C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-07-21T06:46:15Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Chang Y.-L.; Su K.-Y.; Hsu C.-L.; Liu Y.-N.; Chen K.-Y.; Tsai T.-H.; Liao W.-Y.; CHAO-CHI HO; Yang C.-Y. |
| 臺大學術典藏 |
2020-07-21T06:25:17Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Liao W.-Y.; Ho C.-C.; Liao B.-C.; Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tzu-Hsiu Tsai;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Yang J.C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Lee J.-H.; Chang Y.-L.; Su K.-Y.; Hsu W.-H.; Hsu C.-L.; TZU-HSIU TSAI; Chen K.-Y. |
| 臺大學術典藏 |
2020-07-21T06:09:13Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Yang J.C.-H.; Chang Y.-C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Chen K.-Y.; Ho C.-C.; WEI-YU LIAO; Yang P.-C.; Chen H.-Y.; Hsu W.-H.; Lin Y.-L.; Lee J.-H.; Lee J.-H.;Lin Y.-L.;Hsu W.-H.;Chen H.-Y.;Chang Y.-C.;Yu C.-J.;Shih J.-Y.;Lin C.-C.;Chen K.-Y.;Ho C.-C.;Wei-Yu Liao;Yang P.-C.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:08Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Wei-Yu Liao;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; WEI-YU LIAO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:09:03Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Chen K.-Y.; Tsai T.-H.; Ho C.-C.; WEI-YU LIAO; Yang C.-Y.; Yang C.-Y.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yu C.-J.; Yang J.C.-H.; Shih J.-Y.; Lin C.-C.; Lee J.-H.; Hsu W.-H.; Liao B.-C.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C. |
| 臺大學術典藏 |
2020-07-21T05:40:29Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Lee J.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Ching-Yao Yang;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; CHING-YAO YANG; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H. |
| 臺大學術典藏 |
2020-06-30T08:51:15Z |
High expression of high-mobility group box 1 in the blood and lungs is associated with the development of chronic obstructive pulmonary disease in smokers
|
Ko H.-K.;Hsu W.-H.;Hsieh C.-C.;Lien T.-C.;Tzong-Shyuan Lee;Kou Y.R.; Ko H.-K.; Hsu W.-H.; Hsieh C.-C.; Lien T.-C.; TZONG-SHYUAN LEE; Kou Y.R. |
| 臺大學術典藏 |
2020-06-30T08:09:57Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Kang-Yi Su;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; KANG-YI SU; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-30T08:09:52Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-30T08:09:51Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-19T02:27:07Z |
Evaluation of the medicinal herb Graptopetalum paraguayense as a treatment for liver cancer
|
Hsu W.-H.;Chang C.-C.;Kai-Wen Huang;Chen Y.-C.;Hsu S.-L.;Wu L.-C.;Tsou A.-P.;Lai J.-M.;Huang C.-Y.F.; Hsu W.-H.; Chang C.-C.; KAI-WEN HUANG; Chen Y.-C.; Hsu S.-L.; Wu L.-C.; Tsou A.-P.; Lai J.-M.; Huang C.-Y.F. |
| 臺大學術典藏 |
2020-06-19T02:27:00Z |
Graptopetalum paraguayense inhibits liver fibrosis by blocking TGF-β signaling in vivo and in vitro
|
Hsu W.-H.;Liao S.-C.;Chyan Y.-J.;Kai-Wen Huang;Hsu S.-L.;Chen Y.-C.;Siu M.-L.;Chang C.-C.;Chung Y.-S.;Huang C.-Y.F.; Hsu W.-H.; Liao S.-C.; Chyan Y.-J.; KAI-WEN HUANG; Hsu S.-L.; Chen Y.-C.; Siu M.-L.; Chang C.-C.; Chung Y.-S.; Huang C.-Y.F. |
| 臺大學術典藏 |
2020-06-11T06:28:07Z |
Design for a flexible autostereoscopic display with different radius of curvature
|
Cheng, Y.-T.;Huang, K.-C.;Lin, H.Y.;Hsu, W.-H.;Hsiao, L.-J.; Cheng, Y.-T.; Huang, K.-C.; Lin, H.Y.; Hsu, W.-H.; Hsiao, L.-J.; HOANG-YAN LIN |
| 臺大學術典藏 |
2020-06-11T06:28:07Z |
Image quality factors for designs of an autostereoscopic display
|
Cheng, Y.-T.;Hsu, W.-H.;Huang, K.-C.;Lin, H.Y.; Cheng, Y.-T.; Hsu, W.-H.; Huang, K.-C.; Lin, H.Y.; HOANG-YAN LIN |
| 臺大學術典藏 |
2020-06-11T06:21:32Z |
A latent semantic retrieval and clustering system for personal photos with sparse speech annotation
|
LIN-SHAN LEE; Lee, L.-S.; Fu, Y.-S.; Hsu, W.H.; Fu, Y.-S.;Hsu, W.H.;Lee, L.-S. |
| 臺大學術典藏 |
2020-05-26T09:27:00Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Lee J.-H; Lin Y.-L; Hsu W.-H; Chen H.-Y; Chang Y.-C; Yu C.-J; Shih J.-Y; Lin C.-C; Chen K.-Y; Ho C.-C; Laio W.-Y; Yang P.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Yu C.-J.;Chih-Hsin Yang;Shih J.-Y;Lin C.-C;Lee J.-H;Chang Y.-L;Su K.-Y;Hsu W.-H;Hsu C.-L;Tsai T.-H;Chen K.-Y;Liao W.-Y;Ho C.-C;Liao B.-C;Yang C.-Y;Lin S.-Y; Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:32Z |
Overview of current systemic management of EGFR-mutant NSCLC
|
Loong H.H.;Mok T.S;Chih-Hsin Yang;Hsu W.-H; Hsu W.-H; CHIH-HSIN YANG; Mok T.S; Loong H.H. |
| 臺大學術典藏 |
2020-05-26T09:26:17Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y;Liao W.-Y;Ho C.-C;Chen K.-Y;Tsai T.-H;Hsu C.-L;Su K.-Y;Chang Y.-L;Wu C.-T;Hsu C.-C;Liao B.-C;Hsu W.-H;Lee J.-H;Lin C.-C;Shih J.-Y;Chih-Hsin Yang;Yu C.-J.; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Su K.-Y; Chang Y.-L; Wu C.-T; Hsu C.-C; Liao B.-C; Hsu W.-H; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:13Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Chia-Chi Lin; Shih J.-Y; Yang J.C; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:03Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yu C.-J.; Yang J.C.-H; Shih J.-Y; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Liu Y.-N; Su K.-Y; Chang Y.-L; Wu C.-T; Liao B.-C; Hsu C.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Su K.-Y; Chang Y.-L; Wu C.-T; Hsu C.-C; Liao B.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin; Shih J.-Y; Yang J.C.-H; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T02:46:18Z |
Rosiglitazone (BRL 49653) Enhances Insulin Secretory Response via Phosphatidylinositol 3-Kinase Pathway
|
Yang C.;Tien-Jyun Chang;Chang J.-C.;Liu M.-W.;Tai T.-Y.;Hsu W.H.;Chuang L.-M.; Yang C.; TIEN-JYUN CHANG; Chang J.-C.; Liu M.-W.; Tai T.-Y.; Hsu W.H.; Chuang L.-M. |
| 臺大學術典藏 |
2020-05-04T08:22:00Z |
NTU TRECVID-2007 fast rushes summarization system
|
Pan, C.-M.; Chuang, Y.-Y.; Hsu, W.H.; YUNG-YU CHUANG |
| 臺大學術典藏 |
2020-05-04T08:08:57Z |
A middleware architecture to improve the efficiency of web-based telemedicine application
|
Lin, C.-C.; Hsu, W.-H.; Chen, J.-H.; Chen, H.-S.; Chen, C.-Y.; Hou, S.-M.; WINSTON HSU |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer
|
Liang Y.-H.;Wei C.-H.;Hsu W.-H.;Yu-Yun Shao;Lin Y.-C.;Chou P.-C.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Wei C.-H.; Hsu W.-H.; YU-YUN SHAO; Lin Y.-C.; Chou P.-C.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-09T09:43:08Z |
Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer
|
Wei, C. H.; Liang, Y. H.; Hsu, W. H.; Shao, Y. Y.; Lin, Y. C.; Chou, P. C.; Cheng, A. L.; Yeh, K. H. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Yih-Leong Chang;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-07T06:56:09Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Yih-Leong Chang;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-06T08:25:11Z |
MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol
|
Yu Y.-H.; Chen H.-A.; Chen P.-S.; Cheng Y.-J.; Hsu W.-H.; Chang Y.-W.; Chen Y.-H.; Jan Y.; Hsiao M.; Chang T.-Y.; Liu Y.-H.; YUNG-MING JENG; Wu C.-H.; Huang M.-T.; Su Y.-H.; Hung M.-C.; Chien M.-H.; Chen C.-Y.; Kuo M.-L.; Su J.-L. |
| 臺大學術典藏 |
2020-03-06T05:26:04Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-06T05:26:00Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-06T03:25:31Z |
Transitioning to a communication-oriented pedagogy: Taiwanese university freshmen's views on class participation
|
Hsu, W.-H.; Hsu, W.-H.; WEN-HSIEN HSU |
| 臺大學術典藏 |
2020-02-27T06:39:26Z |
Management of Crohn's disease in Taiwan: Consensus guideline of the Taiwan society of inflammatory bowel disease
|
Wei S.-C.;Chang T.-A.;Chao T.-H.;Chen J.-S.;Chou J.-W.;Chou Y.-H.;Chuang C.-H.;Hsu W.-H.;Huang T.-Y.;Hsu T.-C.;Lin C.-C.;Lin H.-H.;Lin J.-K.;Lin W.-C.;Ni Y.-H.;Ming-Jium Shieh;Shih I.-L.;Shun C.-T.;Tsang Y.-M.;Wang C.-Y.;Wang H.-Y.;Weng M.-T.;Wu D.-C.;Wu W.-C.;Yen H.-H.;Wong J.-M.; Wei S.-C.; Chang T.-A.; Chao T.-H.; Chen J.-S.; Chou J.-W.; Chou Y.-H.; Chuang C.-H.; Hsu W.-H.; Huang T.-Y.; Hsu T.-C.; Lin C.-C.; Lin H.-H.; Lin J.-K.; Lin W.-C.; Ni Y.-H.; MING-JIUM SHIEH; Shih I.-L.; Shun C.-T.; Tsang Y.-M.; Wang C.-Y.; Wang H.-Y.; Weng M.-T.; Wu D.-C.; Wu W.-C.; Yen H.-H.; Wong J.-M. |
